TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05529446

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Combination therapy (CT)
Description: Two therapeutic modalities at the same site is described as combination therapy (CT). The most commonly used CT is US \& TENS where this approach was effective in pain modulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination therapy (CT)
Description: Two therapeutic modalities at the same site is described as combination therapy (CT). The most commonly used CT is US \& TENS where this approach was effective in pain modulation
Study: NCT06358235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: 30-minute music therapy session.

Intervention type: OTHER
Group type: OTHER
Intervention: No Music therapy
Description: The practice where patients are simply fitted with headphones and rest quietly without listening to music.
Study: NCT06434623

Intervention type: OTHER
Intervention: patient record
Description: using patient record to construct AI models
Study: NCT05184543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Exercise Program
Description: 8 weeks of routine basketball training will be done. Dynamic stretching exercises, in which large muscle groups are exercised, can be applied for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Exercise Program
Description: In addition to the 8-week routine basketball training, 20 min core stability exercises will be given to the Core Group. Core stability exercises will be performed on the stable surface for the first 4 weeks, and core stability exercises will be performed on unstable surfaces for the next 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Weight Neuromuscular Warm-Up Program
Description: Each 20-minute program consists of 5 different parts. The beginning of the program consists of low-speed running exercises with the ball. The running track for each exercise will include 4 basketball court areas. The second part consists of active stretching exercises. The third part consists of exercises focusing on general strength. The fourth part consists of plyometric, balance, and jump exercises. The final section consists of a sprint with sudden changes of direction and basketball movements.
Study: NCT03763357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat Therapy (HT)
Description: Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.
Study: NCT05329324

Intervention type: OTHER
Intervention: Questionnaire for study group
Description: Demographic features, Stage and Type, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.

Intervention type: OTHER
Intervention: Questionnaire for control group
Description: Demographic features, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
Study: NCT05344339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal gastrectomy
Description: Reconstruction after Distal Gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal gastrectomy
Description: Reconstruction after Distal Gastrectomy
Study: NCT06218576

Intervention type: OTHER
Intervention: None, purely observational study
Description: None, purely observational study
Study: NCT06251245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Injector
Description: * Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* • Experimental Group (Giving the medicine orally to the child with an Oral Injector)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2
Study: NCT04920721

Intervention type: OTHER
Intervention: no intervention
Description: no intervention descriptiv study
Study: NCT06251245

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spoon
Description: * Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* Control Group (Giving the medicine orally to the child with an oral medication spoon)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2
Study: NCT05384535

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bi-parametric MRI
Description: When used for the evaluation of prostate cancer, MRI typically involves multiple sequences and typically includes typical T1 and T2 phases with the addition of diffusion weighted imaging and dynamic contrast enhanced imaging. In this study, we have decided to omit dynamic contrast enhanced imaging due to its decreased diagnostic yield relative to T2 and DWI and associated increased risk of contrast agents, this is a common approach for prostate cancer screening and is referred to as a bi-parametric MRI
Study: NCT04864132

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test
Description: This test assesses submaximal exercise capacity.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test
Description: This test assesses submaximal exercise capacity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Incremental shuttle walk test
Description: This test assesses maximal exercise capacity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Incremental shuttle walk test
Description: This test assesses maximal exercise capacity.
Study: NCT05575505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline 400 MG
Description: Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
Study: NCT05500352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperglycemia with slow decline in plasma glucose in type 1 diabetes
Description: Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperglycemia with rapid decline in plasma glucose in type 1 diabetes
Description: Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound hyperglycemia in type 1 diabetes
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound euglycemia in type 1 diabetes
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in euglycemia (PG: 5-8 mmol/L).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycemia in type 1 diabetes
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L) or euglycemia (PG: 5-8 mmol/L)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycemia in type 2 diabetes
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycemia in healthy controls
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperglycemia in type 2 diabetes
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperglycemia in healthy controls
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
Study: NCT05585710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Lavage Washout
Description: Use of pressurized, pulsed triple antibiotic solution to irrigate mastectomy pocket
Study: NCT06634433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Personnel Attitude
Description: The intervention consists of a two-phase Training of Trainers Program (TTP) designed for health professionals aimed at enhancing interprofessional education (IPE) skills. Phase 1 includes three days of online theoretical training, focusing on topics such as interprofessional collaboration, communication, and conflict resolution. Phase 2 involves two days of face-to-face practical sessions, where participants engage in scenario-based learning and small group discussions to apply IPE concepts. The effectiveness of the program is assessed through pre-test and post-test evaluations, measuring changes in participants\&#39; knowledge, attitudes, and competencies in interprofessional education.
Study: NCT05585710

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant-based breast reconstruction
Description: Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant-based breast reconstruction
Description: Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral or unilateral mastectomy
Description: Standard of care
Study: NCT04880473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrevisEA device
Description: The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
Study: NCT04311671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: 2 mg tablets, encapsulated for blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: 2 mg tablets, encapsulated for blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: 3 mg tablets, encapsulated for blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: 3 mg tablets, encapsulated for blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: 400 mg tablets
Study: NCT06571513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: During session one of the written exposure therapy intervention, the therapist will provide psychoeducation about PTSD and the rationale for the proposed intervention. Psychoeducation and treatment rationale are scripted to ensure consistency. The therapist will provide the participant with instructions for writing about the same trauma memory (their recent sexual assault) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
Study: NCT05585710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral or unilateral mastectomy
Description: Standard of care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue expander
Description: Standard of care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue expander
Description: Standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acellular dermal matrix
Description: Standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix
Description: Standard of care
Study: NCT06571513

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unemotional Writing
Description: During the unemotional writing sessions, the therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did the day before the session from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. The participant will self report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
Study: NCT06570187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be administered with an initial dose of 0.2 μg/kg/hour, infusion rate is to be titrated based on response for at least 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered as the comparator sedative with the standard treatment of sepsis and septic shock.
Study: NCT06305143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: participants with diabetic macular edema (DME) combined with severe non-proliferative diabetes retinopathy (sNPDR) were assigned to anti-VEGF therapy over 12 months.
Study: NCT05320211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed hand orthosis
Description: 3D-printed hand orthoses (intervention) will be compared with custom-fabricated conventional orthoses (control condition at baseline)
Study: NCT02129751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrobromide
Description: study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo arm
Study: NCT06510244

Intervention type: DEVICE
Intervention: EEG EMOTIV
Description: The teeth will be dried with 2x2 gauze; then, Endo Ice will be applied. The patient response will be written on a sheet numbering to choose from 0 to 10, and at the same time, the brain waves will be recorded through EEG.
Study: NCT06144437

Intervention type: DIAGNOSTIC_TEST
Intervention: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)
Description: Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Gastroscopy will be completed and reported by experienced endoscopists, requiring no more than 1 month between gastroscopy and ultrasound examination, and patients should fast for at least 8 hours before gastroscopy.
Study: NCT05146635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Bcg
Description: Patients will receive induction and maintenance BCG after complete TURBT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical chemotherapy (epirubicin)
Description: Patients will receive induction and maintenance epirubicin after complete TURBT.
Study: NCT05226364

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber tourniquet
Description: The blood sample is taken with a rubber tourniquet

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fabric tourniquet
Description: The blood sample is taken with a fabric tourniquet

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without tourniquet
Description: The blood sample is taken without tourniquet
Study: NCT06160856

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound
Description: Measurement of venous congestion in abdominal target-organs (liver, kidneys) by calculating VExUS score

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound
Description: Measurement of venous congestion in abdominal target-organs (liver, kidneys) by calculating VExUS score
Study: NCT06633692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head down tilt (HDT)
Description: In the head-down tilt intervention, a participant is positioned on a tilt table, initially in supine position and afterwards with their head inclined downward at a specific angle. This position causes a shift of body fluids towards the head, mimicking the fluid redistribution observed in microgravity conditions in space.
Study: NCT05603533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music and video-based group exercise therapy
Description: Each exercise session will last up to 45min. The participants will follow this group exercise therapy twice a week for four months.
Study: NCT05071222

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ARTEGENE drug product
Description: Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.
Study: NCT03532373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preference Elicitation tool
Description: A preference elicitation tool for carpal tunnel syndrome
Study: NCT04687683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions. This stretching exercise will be applied in 5 repetitions for one session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolytic Stretching Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions for one session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching Group Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions for one session.
Study: NCT04727047

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular electrical stimulation
Description: All subjects will receive standard rehabilitation for Achilles tendon repair. In addition, neuromuscular electrical stimulation will be applied to the calf muscles of the injured leg. The stimulation volume, the electrode placement and the intensity of the stimulation will be selected based on the mechanical strength of healing Achilles tendon. The intervention will be applied for 6 weeks after repair.
Study: NCT05725460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dextrose 5% median nerve hydrodissection
Description: planned to be a good alternative to steroid hydrodissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dextrose 5% median nerve hydrodissection
Description: planned to be a good alternative to steroid hydrodissection